{
  "docId": "019de070-19a4-704e-b5bc-b8f4ae0c7550",
  "docSlug": "2cfade3d34acc49c8d5f05063b654956",
  "documentTitle": "ATAI | Investor Presentation Deck | 49 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 49,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-19a4-704e-b5bc-b8f4ae0c7550/23",
  "deckHref": "/decks/019de070-19a4-704e-b5bc-b8f4ae0c7550",
  "deckJsonHref": "/decks/019de070-19a4-704e-b5bc-b8f4ae0c7550.json",
  "deckAnchorHref": "/decks/019de070-19a4-704e-b5bc-b8f4ae0c7550#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.9,
        "x": 0.05,
        "y": 0.265
      },
      "kind": "table",
      "text": "Comparison table of 7 compounds across 5 attributes: Compound, Development stage, Mechanism of action, Focused on treating cognitive impairment, Potential for complimentary use with other therapies.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a1e6956-e218-4215-8004-f6a4fe214737",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "CIAS & Schizophrenia landscape: RL-007's unique pharmacology, acute cognitive benefit and excellent tolerability differentiate it from the current standard of care available to CIAS & Schizophrenia patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "60a41e33-abcb-448c-9712-79827b13bd28",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "6c5444b1-879f-46a9-86d2-fd49a839a353",
      "evidence": "table/data: Comparison table of 7 compounds across 5 attributes: Compound, Development stage, Mechanism of action, Focused on treating cognitive impairment, Potential for complimentary use with other therapies.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "4a44306d-de7c-49e2-b888-27418faf75fb",
      "evidence": "Table comparing RL-007 against 6 competitors across key clinical attributes.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}